These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 26134402)

  • 1. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
    Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
    J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The homologous carboxyl-terminal domains of microtubule-associated protein 2 and TAU induce neuronal dysfunction and have differential fates in the evolution of neurofibrillary tangles.
    Xie C; Miyasaka T; Yoshimura S; Hatsuta H; Yoshina S; Kage-Nakadai E; Mitani S; Murayama S; Ihara Y
    PLoS One; 2014; 9(2):e89796. PubMed ID: 24587039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies.
    Sontag JM; Nunbhakdi-Craig V; White CL; Halpain S; Sontag E
    J Biol Chem; 2012 Apr; 287(18):14984-93. PubMed ID: 22403409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of NFT: Biochemical Approach.
    Hasegawa M
    Adv Exp Med Biol; 2019; 1184():23-34. PubMed ID: 32096025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assembly of filamentous tau aggregates in human neuronal cells.
    Ko LW; Rush T; Sahara N; Kersh JS; Easson C; Deture M; Lin WL; Connor YD; Yen SH
    J Alzheimers Dis; 2004 Dec; 6(6):605-22; discussion 673-81. PubMed ID: 15665401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
    Bakota L; Ussif A; Jeserich G; Brandt R
    Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsically disordered tau protein in Alzheimer's tangles: a coincidence or a rule?
    Skrabana R; Skrabanova M; Csokova N; Sevcik J; Novak M
    Bratisl Lek Listy; 2006; 107(9-10):354-8. PubMed ID: 17262987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau and tauopathies.
    Robert M; Mathuranath PS
    Neurol India; 2007; 55(1):11-6. PubMed ID: 17272893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular models for tau filament assembly.
    Ko LW; DeTure M; Sahara N; Chihab R; Yen SH
    J Mol Neurosci; 2002 Dec; 19(3):311-6. PubMed ID: 12540057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sources of extracellular tau and its signaling.
    Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
    J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation.
    Wang C; Terrigno M; Li J; Distler T; Pandya NJ; Ebeling M; Tyanova S; Hoozemans JJM; Dijkstra AA; Fuchs L; Xiang S; Bonni A; Grüninger F; Jagasia R
    Neuron; 2023 Sep; 111(17):2660-2674.e9. PubMed ID: 37385246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azure C Targets and Modulates Toxic Tau Oligomers.
    Lo Cascio F; Kayed R
    ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau, tau kinases, and tauopathies: An updated overview.
    Montalto G; Ricciarelli R
    Biofactors; 2023; 49(3):502-511. PubMed ID: 36688478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.